Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Forest Lexapro maintenance claim

Executive Summary

Forest Lexapro receives supplemental approval for prevention of relapse following long-term treatment of major depressive disorder Aug. 29. Escitalopram longer-term efficacy data will replace data from the predecessor antidepressant Celexa (citalopram) in Lexapro's Aug. 14 approved labeling (1"The Pink Sheet" Aug. 19, p. 3). The sNDA was filed Oct. 29, seven months after the NDA was filed...

You may also be interested in...

Forest Lexapro Approval Includes Label Claim Of Greater Potency Than Celexa

Forest's Lexapro (escitalopram) label includes a statement of greater potency than its predecessor antidepressant Celexa (citalopram)

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.

In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is

President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts